ChloroquineV1, Main, Exploration, bibRecord, 002F01

The effect of dapsone in steroid-dependent asthma

Identifieur interne : 002F01 ( Main/Exploration ); précédent : 002F00; suivant : 002F02

The effect of dapsone in steroid-dependent asthma

Auteurs : Bruce A. Berlow [États-Unis] ; Myron I. Liebhaber [États-Unis] ; Zeb Dyer [États-Unis] ; Timothy M. Spiegel [États-Unis]

Source :

The Journal of Allergy and Clinical Immunology [ 0091-6749 ] ; 1991.

RBID : ISTEX:F68538CD2A7B31C1CAE46A85C714F0DB9D38368C

English descriptors

Teeft :
- Additional patients, Airway, Airway hyperresponsiveness, Allergy, Allergy clin immunol, Allergyclin immunol, Animal model, Asthma, Asthmatic, Asthmatic reactions, Baseline, Baseline period, Baseline prednisone dose, Bronchial asthma, Bronchoalveolar lavage, Carbon monoxide, Chemotactic, Chronic asthma, Clin, Complete blood count, Cutaneous reactions, Dapsone, Data analysis, Decreases neutrophil, Guinea pigs, Human monocytes, Human neutrophils, Immunol, Immunology division, Inflammatory, Inflammatory disorders, Inhaled steroids, Late asthmatic reactions, Late asthmatic response, Mast cell granules, Nebulization frequency, Neutrophil, Neutrophil chemotactic activity, Neutrophil chemotactic factor, Neutrophil depletion, Neutrophil function, Open study, Ozone exposure, Possible role, Preliminary findings, Publication july, Respir, Sansummedical clinic, Santa barbara, Severe asthma, Short courses, Significant anemia, Status asthmaticus, Steroid, Steroid dose, Steroid reduction, Study design, Symptom scores, Theophylline, Theophylline clearance, Theophylline level, Theophylline levels, Toluene asthma, Toluene diisocyanate.

Abstract

Abstract: We studied the steroid-sparing effect of dapsone in 10 subjects with chronic asthma in a preliminary open trial. Dapsone was chosen because it inhibits neutrophil function and possesses anti-inflammatory effects in a variety of disorders. The study group consisted of 10 subjects with stable, steroid-dependent asthma, aged 23 to 80 years, with normal glucose-6-phosphate dehydrogenase levels. Average daily baseline prednisone dose ranged from 5 to 60 mg. Dapsone, 100 mg, twice daily, by mouth, was started after a 1-month baseline period. Baseline steroid dose, symptom scores, and daily peak flow rates were compared to the latest available 4-week period of dapsone treatment. Average cumulative monthly prednisone dose was reduced from 428 mg to 82 mg (p < 0.02). Five of 10 patients stopped steroids by month 6 and two additional patients by month 13. Two additional patients demonstrated a coincidental 74% reduction in steroid dose, and one patient demonstrated no response. Clinical parameters remained stable despite steroid reduction. These preliminary data suggest dapsone may have steroid-sparing effects in chronic asthma.

Url:

https://api.istex.fr/ark:/67375/6H6-FC8LM4T8-L/fulltext.pdf

DOI: 10.1016/0091-6749(91)90393-3

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001161
to stream Istex, to step Curation: 001161
to stream Istex, to step Checkpoint: 001C71
to stream Main, to step Merge: 002F68
to stream Main, to step Curation: 002F01

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The effect of dapsone in steroid-dependent asthma</title>
<author><name sortKey="Berlow, Bruce A" sort="Berlow, Bruce A" uniqKey="Berlow B" first="Bruce A." last="Berlow">Bruce A. Berlow</name>
</author>
<author><name sortKey="Liebhaber, Myron I" sort="Liebhaber, Myron I" uniqKey="Liebhaber M" first="Myron I." last="Liebhaber">Myron I. Liebhaber</name>
</author>
<author><name sortKey="Dyer, Zeb" sort="Dyer, Zeb" uniqKey="Dyer Z" first="Zeb" last="Dyer">Zeb Dyer</name>
</author>
<author><name sortKey="Spiegel, Timothy M" sort="Spiegel, Timothy M" uniqKey="Spiegel T" first="Timothy M." last="Spiegel">Timothy M. Spiegel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F68538CD2A7B31C1CAE46A85C714F0DB9D38368C</idno>
<date when="1991" year="1991">1991</date>
<idno type="doi">10.1016/0091-6749(91)90393-3</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-FC8LM4T8-L/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001161</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001161</idno>
<idno type="wicri:Area/Istex/Curation">001161</idno>
<idno type="wicri:Area/Istex/Checkpoint">001C71</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001C71</idno>
<idno type="wicri:doubleKey">0091-6749:1991:Berlow B:the:effect:of</idno>
<idno type="wicri:Area/Main/Merge">002F68</idno>
<idno type="wicri:Area/Main/Curation">002F01</idno>
<idno type="wicri:Area/Main/Exploration">002F01</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">The effect of dapsone in steroid-dependent asthma</title>
<author><name sortKey="Berlow, Bruce A" sort="Berlow, Bruce A" uniqKey="Berlow B" first="Bruce A." last="Berlow">Bruce A. Berlow</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Santa Barbara, Calif.</wicri:regionArea>
<wicri:noRegion>Calif.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liebhaber, Myron I" sort="Liebhaber, Myron I" uniqKey="Liebhaber M" first="Myron I." last="Liebhaber">Myron I. Liebhaber</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Santa Barbara, Calif.</wicri:regionArea>
<wicri:noRegion>Calif.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dyer, Zeb" sort="Dyer, Zeb" uniqKey="Dyer Z" first="Zeb" last="Dyer">Zeb Dyer</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Santa Barbara, Calif.</wicri:regionArea>
<wicri:noRegion>Calif.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Spiegel, Timothy M" sort="Spiegel, Timothy M" uniqKey="Spiegel T" first="Timothy M." last="Spiegel">Timothy M. Spiegel</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Santa Barbara, Calif.</wicri:regionArea>
<wicri:noRegion>Calif.</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">The Journal of Allergy and Clinical Immunology</title>
<title level="j" type="abbrev">YMAI</title>
<idno type="ISSN">0091-6749</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1991">1991</date>
<biblScope unit="volume">87</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="710">710</biblScope>
<biblScope unit="page" to="715">715</biblScope>
</imprint>
<idno type="ISSN">0091-6749</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0091-6749</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Additional patients</term>
<term>Airway</term>
<term>Airway hyperresponsiveness</term>
<term>Allergy</term>
<term>Allergy clin immunol</term>
<term>Allergyclin immunol</term>
<term>Animal model</term>
<term>Asthma</term>
<term>Asthmatic</term>
<term>Asthmatic reactions</term>
<term>Baseline</term>
<term>Baseline period</term>
<term>Baseline prednisone dose</term>
<term>Bronchial asthma</term>
<term>Bronchoalveolar lavage</term>
<term>Carbon monoxide</term>
<term>Chemotactic</term>
<term>Chronic asthma</term>
<term>Clin</term>
<term>Complete blood count</term>
<term>Cutaneous reactions</term>
<term>Dapsone</term>
<term>Data analysis</term>
<term>Decreases neutrophil</term>
<term>Guinea pigs</term>
<term>Human monocytes</term>
<term>Human neutrophils</term>
<term>Immunol</term>
<term>Immunology division</term>
<term>Inflammatory</term>
<term>Inflammatory disorders</term>
<term>Inhaled steroids</term>
<term>Late asthmatic reactions</term>
<term>Late asthmatic response</term>
<term>Mast cell granules</term>
<term>Nebulization frequency</term>
<term>Neutrophil</term>
<term>Neutrophil chemotactic activity</term>
<term>Neutrophil chemotactic factor</term>
<term>Neutrophil depletion</term>
<term>Neutrophil function</term>
<term>Open study</term>
<term>Ozone exposure</term>
<term>Possible role</term>
<term>Preliminary findings</term>
<term>Publication july</term>
<term>Respir</term>
<term>Sansummedical clinic</term>
<term>Santa barbara</term>
<term>Severe asthma</term>
<term>Short courses</term>
<term>Significant anemia</term>
<term>Status asthmaticus</term>
<term>Steroid</term>
<term>Steroid dose</term>
<term>Steroid reduction</term>
<term>Study design</term>
<term>Symptom scores</term>
<term>Theophylline</term>
<term>Theophylline clearance</term>
<term>Theophylline level</term>
<term>Theophylline levels</term>
<term>Toluene asthma</term>
<term>Toluene diisocyanate</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: We studied the steroid-sparing effect of dapsone in 10 subjects with chronic asthma in a preliminary open trial. Dapsone was chosen because it inhibits neutrophil function and possesses anti-inflammatory effects in a variety of disorders. The study group consisted of 10 subjects with stable, steroid-dependent asthma, aged 23 to 80 years, with normal glucose-6-phosphate dehydrogenase levels. Average daily baseline prednisone dose ranged from 5 to 60 mg. Dapsone, 100 mg, twice daily, by mouth, was started after a 1-month baseline period. Baseline steroid dose, symptom scores, and daily peak flow rates were compared to the latest available 4-week period of dapsone treatment. Average cumulative monthly prednisone dose was reduced from 428 mg to 82 mg (p < 0.02). Five of 10 patients stopped steroids by month 6 and two additional patients by month 13. Two additional patients demonstrated a coincidental 74% reduction in steroid dose, and one patient demonstrated no response. Clinical parameters remained stable despite steroid reduction. These preliminary data suggest dapsone may have steroid-sparing effects in chronic asthma.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Berlow, Bruce A" sort="Berlow, Bruce A" uniqKey="Berlow B" first="Bruce A." last="Berlow">Bruce A. Berlow</name>
</noRegion>
<name sortKey="Dyer, Zeb" sort="Dyer, Zeb" uniqKey="Dyer Z" first="Zeb" last="Dyer">Zeb Dyer</name>
<name sortKey="Liebhaber, Myron I" sort="Liebhaber, Myron I" uniqKey="Liebhaber M" first="Myron I." last="Liebhaber">Myron I. Liebhaber</name>
<name sortKey="Spiegel, Timothy M" sort="Spiegel, Timothy M" uniqKey="Spiegel T" first="Timothy M." last="Spiegel">Timothy M. Spiegel</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F01 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F01 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F68538CD2A7B31C1CAE46A85C714F0DB9D38368C
   |texte=   The effect of dapsone in steroid-dependent asthma
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

The effect of dapsone in steroid-dependent asthma

The effect of dapsone in steroid-dependent asthma

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri